NEW HAVEN, CT, and TORONTO, Nov. 13 /PRNewswire/ - BioRelix, pioneers in the discovery and development of RiboSwitch based therapeutic agents and Dalton Medicinal Chemistry, have jointly announced a research collaboration to discover new therapeutics.
Dalton Medicinal Chemistry will utilize their proprietary insights to design and synthesize several novel classes of compounds against selected RiboSwitch targets. BioRelix will advance these compounds using their cutting edge battery of biological assays and thorough knowledge of RiboSwitch drug discovery and development.
Brian Dixon, BioRelix CEO commented: “We are pleased to have the opportunity to work with the creative team at Dalton Medicinal Chemistry in the discovery of new entities for treating infectious diseases. Their expertise, coupled with our proprietary and leading position in RiboSwitch technology will lead to important new medicines.”
Judd Berman, Co-founder of Dalton Medicinal Chemistry, said: “We are delighted to have this opportunity to work with BioRelix in the discovery of much needed new anti-infective agents. The team at BioRelix has clearly established an exceptionally innovative approach to anti-infectives.”
About BioRelix
BioRelix Pharmaceuticals, Inc. is a drug discovery and development company focused on identifying new anti-infective drug treatments. BioRelix is building a portfolio of anti-infective products based on novel patented RNA targets, termed RiboSwitches, which were identified in the laboratory of BioRelix co-founder, Ronald Breaker Ph.D., Howard Hughes Investigator and Henry Ford II Professor at Yale University. BioRelix investors include CHL Medical Partners, New Leaf Venture Partners, Aisling Capital, Novartis Venture Fund, Elm Street Ventures and Alexandria Real Estate Equities.
About Dalton Pharma Services
Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved contract pharmaceutical manufacturer that supplies chemistry and analytical services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. Dalton provides cGMP manufacturing and sterile filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its state of the art cGMP facilities, Dalton produces active pharmaceutical ingredients at the gram or kilogram scale. Dalton conducts sterile fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton’s analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients.
CONTACT: BioRelix, Inc., Brian R. Dixon, (203) 785-9282, www.biorelix.com;
Dalton Pharma Services, Peter Pekos, (416) 661-2102, www.dalton.com